Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, is devoted to building access to safe, science- and evidence-backed psychedelic-assisted therapies globally. “The company has filed a provisional patent application for its pharmaceutical-grade synthetic ibogaine to be used in clinical research and anticipates developing that in conjunction with its software-as-a-service (‘SaaS’) platform iSTRYM,” reads a recent article. iSTRYM is designed to help physicians and patients manage psychiatric medications using smart “digital therapeutics” technology. On August 10, MCURF announced an agreement with Dr. Ken Weingardt to provide consulting services as a senior clinical technology advisor. Weingardt will guide iSTRYM toward near-term commercial deployment, building clinical excellence in both deployment and design. He was quoted as saying, “The company is among the first to develop a digital therapeutic specifically designed to support the process of psychedelic-assisted therapy.”
To view the full article, visit https://ibn.fm/8sDlt
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care solutions, announced a commercial agreement with…
NRx Pharmaceuticals (NASDAQ: NRXP) announced that the U.S. Food and Drug Administration cleared the company to…
Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its positioning as cardiovascular…
Oncotelic Therapeutics (OTCQB: OTLC) announced the consummation of a strategic asset transfer agreement with Lunai Bioworks, Inc., granting…
VolitionRx Limited (NYSE American: VNRX) announced submission for peer review of a clinical manuscript demonstrating the high accuracy…
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has initiated its first commercial manufacturing order of preservative-free…